Figure S7 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

This is a Animal Study study (also classified as: Observational).

Key Points

Co-targeting bcl-xl and mcl-1 results in significant morphological changes in organoids after treatment.
The treatment with BH3 mimetics leads to observable effects, supporting synergistic interactions between agents.
Analysis of LuCaP-167CR organoids highlights the potential benefits of combined therapies in cancer treatment.
These findings may enable improved strategies for targeting resistant prostate cancer variants, enhancing treatment outcomes.

Observational analysis shows morphological changes in organoids treated with BH3 mimetics in CRPC models, indicating potential therapeutic synergy.

Figure S7 depicts morphological changes of the LuCaP-167CR organoids after treatment with BH3 mimetics as single agents or in combination.

No takes yet. Share an insight, caveat, or question.

Brim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share